Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022

BACKGROUND: We estimated SARS‐CoV‐2 Delta‐ and Omicron‐specific effectiveness of two and three mRNA COVID‐19 vaccine doses in adults against symptomatic illness in US outpatient settings. METHODS: Between October 1, 2021, and February 12, 2022, research staff consented and enrolled eligible particip...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sara S., Chung, Jessie R., Talbot, H. Keipp, Grijalva, Carlos G., Wernli, Karen J., Kiniry, Erika, Martin, Emily T., Monto, Arnold S., Belongia, Edward A., McLean, Huong Q., Gaglani, Manjusha, Mamawala, Mufaddal, Nowalk, Mary Patricia, Moehling Geffel, Krissy, Tartof, Sara Y., Florea, Ana, Lee, Justin S., Tenforde, Mark W., Patel, Manish M., Flannery, Brendan, Bentz, Meghan L., Burgin, Alex, Burroughs, Mark, Davis, Morgan L., Howard, Dakota, Lacek, Kristine, Madden, Joseph C., Nobles, Sarah, Padilla, Jasmine, Sheth, Mili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353375/
https://www.ncbi.nlm.nih.gov/pubmed/36825251
http://dx.doi.org/10.1111/irv.13029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353375/
https://www.ncbi.nlm.nih.gov/pubmed/36825251
http://dx.doi.org/10.1111/irv.13029

Ejemplares similares